Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States.

Objective: To report our initial experiences with testosterone undecanoate (TU 750) mg (AVEED) in men with testosterone deficiency.

Methods: All patients receiving TU 750 mg at our center between July 1, 2014, and August 1, 2016, were identified. Clinical response was assessed through structured interviews and laboratory evaluations.